目的 建立注射用盐酸倍他司汀临床合理用药评价标准，为临床合理应用提供参考。方法 以注射用盐酸倍他司汀药品说明书为基础，参考相关指南和专家共识为依据，采用AHP-TOPSIS方法对安徽医科大学附属六安医院2023年1月—12月使用注射用盐酸倍他司汀病历的用药合理性进行评价。结果 共纳入165份病历，其中相对接近度（Ci）≥0.8病历评级为合理，共15例（占比9.09%）；0.6≤Ci＜0.8病历评级为基本合理，共86例（占比52.12%）；Ci＜0.6病历评级为不合理，共64例（占比38.79%）。注射用盐酸倍他司汀用药不合理用药主要表现在适应证、溶媒、给药方式、特殊人群以及疗效评价等方面。结论 本院注射用盐酸倍他司汀的使用仍存在许多问题，需要加强管理。基于AHP-TOPSIS的评价方法科学合理，为药物合理性评价提供了新的方法。

Objective To establish the evaluation criteria for clinical rational drug use of Betahistine Hydrochloride for Injection, and to provide reference for clinical rational application. Methods Based on the drug instructions of Betahistine Hydrochloride for Injection, referring to relevant guidelines and expert consensus, AHP-TOPSIS method was used to evaluate the rationality of the use of Betahistine Hydrochloride for Injection in the Lu’an Hospital Affiliated to Anhui Medical University from January to December 2023. Results A total of 165 medical records were included, of which 15 cases (9.09 %) had a reasonable Ci ≥ 0.8 medical record rating, 86 cases ( 52.12 % ) had a basically reasonable 0.6 ≤ Ci < 0.8 medical record rating, and 64 cases (38.79 %) had an unreasonable Ci < 0.6 medical record rating. The irrational use of Betahistine Hydrochloride for Injection is mainly manifested in indications, solvents, administration methods, special populations and efficacy evaluation. Conclusion There are still many problems in the use of Betahistine Hydrochloride for Injection in the hospital, and management needs to be strengthened. The evaluation method based on AHP-TOPSIS is scientific and reasonable, which provides a new method for the evaluation of drug rationality.

R971

安徽高校自然科学研究项目(KJ2021A0342);六安市科技局科研项目(2022lakj036)